Health Care Checkup

April 24, 2026

THE BIG PICTURE: KEY CONGRESSIONAL & EXECUTIVE BRANCH DEVELOPMENTS


On Tuesday, the House passed three health care bills under suspension of the rules: H.R.2493 (Improving Care in Rural America Reauthorization Act of 2025), H.R.3419 (To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs), and H.R.2319 (Women and Lung Cancer Research and Preventive Services Act of 2025)


On Thursday, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare.


On Thursday, President Trump announced the 17th most-favored-nation (MFN) agreement with a pharmaceutical manufacturer, Regeneron. The agreement will provide every State Medicaid program with access to MFN drug prices for new Regeneron products, guarantee MFN prices for all new medicines Regeneron brings to market, and require the repatriation of increased foreign revenue from existing products that Regeneron realizes as a result of the President’s trade policies. In addition, Regeneron will reduce the price of its cholesterol medicine, Praluent, from $537 to $225 for patients purchasing directly through TrumpRx, and Regeneron’s new gene therapy, Otarmeni, will be given to U.S. patients at no cost as part of the agreement.

What to Expect Next Week:



The House will hold two health hearings next week. On Tuesday, the House Ways and Means Committee will hear from health system CEOs. On Wednesday, the Energy and Commerce Health Subcommittee will examine legislative proposals related to food regulation and oversight.


In the Senate, on Wednesday, the Homeland Security and Governmental Affairs Subcommittee on Investigations will hold a hearing focused on COVID-19 vaccine safety oversight.

DEEP DIVE

Congressional:


House Passes Three Health Care Bills

On Tuesday, the House passed three health care bills under suspension of the rules:

  • H.R.2493 - Improving Care in Rural America Reauthorization Act of 2025: The bill would reauthorize $79.5 million annually through FY2030 grant programs administered by the Health Resources and Services Administration (HRSA) that provide funding to health care service providers and related entities in rural areas. Passed 406 - 4
  • H.R.3419 - To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs: The bill would reauthorize $42.1 million annually through FY2030, federal grants supporting telehealth networks and resource programs. The programs, administered by HRSA, expand access to medical services for rural and underserved patients by helping providers set up telehealth networks. Passed by voice
  • H.R.2319 - Women and Lung Cancer Research and Preventive Services Act of 2025: The bill would require the Department of Health and Human Services to conduct an interagency review to accelerate lung cancer research, prevention, and awareness with respect to women and underserved populations within two years of enactment. Passed by voice

 

House Appropriations Subcommittee Advances FY2027 FDA Funding Bill

On Thursday, the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, National Security, Department of State, and Related Programs voted to advance the fiscal year (FY) 2027 budget bill for the Department of Agriculture and the Food and Drug Administration (FDA) in a 10-7 party-line vote. The legislation, which provides the FDA with $7.1 billion in topline funding, is slightly less than the Trump administration’s $7.2 billion ask for the agency. The bill is slated to be marked up by the full House Appropriations Committee next week on Tuesday, April 28. Read the bill summary here and the bill text here.

 

HHS Secretary Robert F. Kennedy Jr. Testifies at Four Hearings This Week in House & Senate

This week, four House and Senate committees held hearings with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on the Trump Administration's proposed HHS budget for fiscal year 2027. The proposed budget seeks $111.1 billion in discretionary budget authority for the Department of Health and Human Services (HHS) in FY 2027, a $15.8 billion decrease from FY 2026 funding levels, including a $5 billion decrease to the National Institutes of Health (NIH) and a $3.8 billion decrease to the Centers for Disease Control and Prevention (CDC) compared to the funding level Congress approved for FY 2026. The proposed budget also requested a $98.2 billion increase for the Centers for Medicare & Medicaid Services (CMS) and a $7.2 billion increase for the Food and Drug Administration (FDA). Kennedy started the week testifying at the House Energy and Commerce Health Subcommittee and the Senate Appropriations Labor-HHS Subcommittee on Tuesday. He then testified at the Senate Finance Committee and Senate Health, Education, Labor, and Pensions (HELP) Committee on Wednesday. During the hearings, members on both sides of the aisle urged Kennedy not to cut funding for the NIH and ensure the continuation of various public health programs. During the Senate Labor-HHS-Education Appropriations Subcommittee, Ranking Member Patty Murray (D-WA) stated that Kennedy was "picking on an agency that funds research that finds cures." Kennedy argued that many of the dollars that go to the NIH are wasted.


Both Republicans and Democrats also discussed vaccines at several of the hearings, including Senate HELP Chair Bill Cassidy (R-LA), who at the HELP Committee hearing, pressed Kennedy on whether he would allow President Donald Trump's nominee for CDC director, Erica Schwartz, to make independent decisions on vaccines, stating that he was concerned she would not be able to make decisions independently because political appointees in the agency have "worked to undermine trust." Kennedy responded that Cassidy’s “characterization of the political appointees is wrong” and affirmed that the CDC director could make decisions independently. Read Kennedy’s witness testimony here, and Mehlman’s hearing summary of the Senate Finance Committee hearing here.

 

House Ways and Means Committee Holds Hearing on Medicare Fraud

On Tuesday, the House Ways and Means Committee held a hearing to examine Medicare fraud. During the hearing, there was bipartisan agreement that Medicare fraud is a significant problem that harms both taxpayers and vulnerable beneficiaries, and members on both sides supported moving away from a "pay and chase" model toward more proactive, data-driven fraud prevention. Republicans emphasized that Medicare is losing billions of dollars to fraud, highlighting fraudulent schemes in hospice, home health, and durable medical equipment (DME). Democrats criticized Republicans for using fraud as a pretext to cut healthcare benefits, and several Democrats pointed to the Trump Administration for pardoning numerous convicted healthcare fraudsters, firing Inspectors General, and creating a culture of corruption. Read Mehlman’s hearing summary here. 


Notable Bills:


House Oversight Chairman Comer Introduces Legislation to Stop Fraud in Federal Programs

On Thursday, House Committee on Oversight and Government Reform Chairman James Comer (R-KY) introduced two bills to prevent fraud in federal programs. The Stopping Fraudulent Payments Act would prevent federal agencies from making payments when an agency has determined there is an elevated risk of fraud or the payment is likely to be improper. The bill also gives the U.S. Treasury new authority to return payment requests to agencies if they appear to be at risk for fraud. The Pre-Payment Fraud Prevention and Treasury Data Access Act would direct the U.S. Treasury to work with agencies to verify payment and payee information before payments go out the door. Read the press release here.


Representative Joyce and Colleagues Introduce Bipartisan Medicare Advantage Improvement Act (MAIA)

On Thursday, Representative John Joyce, MD (R-PA), introduced the Medicare Advantage Improvement Act (MAIA), bipartisan legislation that would make changes to Medicare Advantage, including prior authorization and payment policies, among other changes. Representatives Kim Schrier, MD (D-WA), Greg Murphy, MD (R-NC), Mariannette Miller-Meeks, MD (R-IA), Jimmy Panetta (D-CA), and Beth Van Duyne (R-TX) are original cosponsors. Read the press release, the bill here, and the section-by-section here.

 

Senator Wyden, Senate Democrats Introduce Legislation to Force Disclosure of Trump Administration Terms with Pharmaceutical Companies

On Tuesday, Senate Finance Committee Ranking Member Ron Wyden (D-OR) and 18 Senate Democrats introduced the Drug Deal Disclosure Act. The legislation would require the Department of Health and Human Services (HHS) to release the details of the deals struck between drug manufacturers and the Trump Administration, including all documentation associated with the agreements, and instructs the Congressional Budget Office and the Government Accountability Office to publish a comprehensive analysis of the economic and budgetary impacts of all disclosed agreements. Read the press release here and the bill here.


Senators Kaine, Budd Introduce Bill to Boost Safety and Security Against Biological Threats

On Tuesday, Senators Tim Kaine (D-VA) and Ted Budd (R-NC) introduced the bipartisan Engineering Biology Readiness Act. The legislation would help safeguard the United States against biological threats by renewing the requirement for a National Biodefense Strategy (NBS) and directing an interagency coalition to provide recommendations to mitigate the risks of frontier biological research. Read the press release here and the bill here.

 

Senator Marshall Introduces Legislation to Expand Health Savings Accounts

On Tuesday, Senator Roger Marshall, M.D. (R-KS), introduced the Health Savings Account (HSA) Expansion Act. The legislation would expand HSA eligibility to people on Medicare, Medicaid, and CHIP, as well as to all private plans that have a deductible above a certain amount, among other changes. Read the press release here and the bill here.


Representatives Smucker, Davids Introduce Bipartisan Accountable Produce is Medicine Act

On Tuesday, Representatives Lloyd Smucker (R-PA) and Sharice Davids (R-KS) introduced the bipartisan Accountable Produce is Medicine Act. The legislation would direct the Center for Medicare and Medicaid Innovation (CMMI) to test a new bundled payment model that integrates “produce prescriptions” interventions into care for patients with chronic diseases. Through this “food is medicine” approach, eligible individuals would gain access to nutrition-focused support, including healthy foods, care coordination, and monitoring services, to improve health outcomes and reduce overall health care costs. Read the press release here and the bill here.

 

Representatives Kelly, DelBene Introduce the Concurrent Care for Comfort Act

On Monday, Representatives Mike Kelly (R-PA) and Suzan DelBene (D-WA) introduced the Concurrent Care for Comfort Act. Currently, Americans living with end-stage renal disease (ESRD) are not permitted to continue their dialysis treatment under Medicare to enter palliative hospice care. This legislation would amend Medicare policy to allow Americans to continue dialysis and enter hospice. Specifically, the legislation would clarify the Medicare coverage policy for palliative dialysis services and the separate payment for such services furnished by renal dialysis facilities and providers to certain individuals electing hospice care. Read the press release here and the bill here. 


Executive Branch:


President Donald Trump Announces Most-Favored-Nation Agreement with Regeneron

On Thursday, President Trump announced the 17th most-favored-nation (MFN) agreement with a pharmaceutical manufacturer, Regeneron. The agreement will provide every State Medicaid program with access to MFN drug prices for new Regeneron products, guarantee MFN prices for all new medicines Regeneron brings to market, and require the repatriation of increased foreign revenue from existing products that Regeneron realizes as a result of the President’s trade policies. In addition, Regeneron will reduce the price of its cholesterol medicine, Praluent, from $537 to $225 for patients purchasing directly through TrumpRx, and Regeneron’s new gene therapy, Otarmeni, will be given to U.S. patients at no cost as part of the agreement. Read the fact sheet here.


Treasury Announces Form 990 Transparency Initiative

On Thursday, the Department of the Treasury announced that the Internal Revenue Service (IRS) plans to revise the Form 990 to improve transparency, strengthen tax administration, and provide clearer reporting on certain activities of tax-exempt organizations described in section 501(c)(3) of the Internal Revenue Code, including government contracts, government grants, and fiscal sponsorship arrangements. The Treasury and the IRS expect to publish proposed regulations and provide an opportunity for public comment before any reporting changes are finalized. Read the press release here.

 

CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices

On Thursday, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare. The RAPID coverage pathway is designed to significantly reduce delays that have historically occurred between FDA market authorization and Medicare national coverage determinations, as CMS will now be a part of the early and frequent engagement between the FDA and device innovators. Read the press release here.

 

President Trump Signs Executive Order to Accelerate Medical Treatments for Serious Mental Illness

On Saturday, President Trump signed an executive order requiring the Food and Drug Administration (FDA) Commissioner to provide the Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designations for treating serious mental illnesses, and that meet the criteria of the National Priority Voucher Program. The order does not call for the rescheduling of psychedelics, but it does require the Justice Department to ready reviews of products containing Schedule 1 substances that have gone through a Phase 3 trial to treat serious mental health disorders to allow for speedier action in case the administration ultimately decides to reschedule a product. Read the fact sheet here.

 

Secretary Kennedy Appoints Casey B. Mulligan as HHS Chief Economist and Regulatory Officer

Late last week, on Friday, the Department of Health and Human Services (HHS) announced the appointment of Casey B. Mulligan, PhD, as Chief Economist and Chief Regulatory Officer. Mulligan is a University of Chicago economist who served as Chief Economist on the Council of Economic Advisers during the first Trump Administration. He most recently served as the U.S. Small Business Administration’s Chief Counsel for Advocacy. Read the press release here. 

CONGRESSIONAL HEARINGS & EVENTS

House:


House Ways and Means Committee – Hearing

“Full Committee Hearing with Health System CEOs”

Tuesday, April 28, at 10:00 AM


House Energy and Commerce Committee, Subcommittee on Health – Hearing

“Healthier America: Legislative Proposals on the Regulation and Oversight of Food.”

Wednesday, April 29, at 2:00 PM


Senate:


Senate Homeland Security and Governmental Affairs Committee, Subcommittee on Investigations

“Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals”

Wednesday, April 29, at 2:30 PM 

ADMINISTRATION ANNOUNCEMENTS

Centers for Medicare & Medicaid Services

Food and Drug Administration

National Institutes of Health

1341 G Street NW
Washington, DC 20005
202-585-0258